VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

WCM/EADO 2021 | 5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma

Georgina Long, PhD, MBBS, FRACP, University of Sydney, Sydney, Australia, talks on adjuvant targeted therapies for patients with melanoma, highlighting five-year results of dabrafenib combined with trametinib versus placebo in resected stage III melanoma (NCT01584648). Five-year results are consistent with three-year results, reporting a relapse-free survival benefit with a risk reduction of 50%. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Disclosures

Georgina Long, PhD, MBBS, FRACP is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDX B.V. and Specialised Therapeutics Australia Pty Ltd.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter